Adbry Pediatric Safety (Ages 12-17)

Proven safety Day in and day out³

Summary of Safety

Adbry® has a demonstrated
pediatric safety profile

Adverse reactions occurring in ≥5% of the Adbry group through Week 16³

Adverse reactions occurring in >5% of the Adbry® (tralokinumab-idrm) group through week 16. Data shown for Adbry® (tralokinumab-idrm) 150 mg q2w and placebo. Adverse reactions incluide viral upper respiratory tract infection, atopic dermatitis, upper respiratory tract infection, injection site reaction, and headache.

q2w=every 2 weeks.

The safety profile of Adbry in pediatric patients (12-17 years), assessed through the initial treatment period of 16 weeks and the long-term period of 52 weeks, was similar to the safety profile from trials in adults.³

q2w=every 2 weeks.

INDICATION

ADBRY^® (tralokinumab-Idrm) injection is indicated for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. ADBRY can be used with or without topical corticosteroids.

Please see full Prescribing Information.

IMPORTANT SAFETY INFORMATION AND INDICATION

IMPORTANT SAFETY INFORMATION

CONTRAINDICATION

ADBRY is contraindicated in patients who have known hypersensitivity to tralokinumab-ldrm or any excipients in ADBRY.

WARNINGS AND PRECAUTIONS

Hypersensitivity: Hypersensitivity reactions, including anaphylaxis and angioedema have occurred after administration of ADBRY. If a serious hypersensitivity reaction occurs, discontinue ADBRY immediately and initiate appropriate therapy.
Conjunctivitis and Keratitis: Conjunctivitis and keratitis occurred more frequently in atopic dermatitis subjects who received ADBRY. Conjunctivitis was the most frequently reported eye disorder. Advise patients to report new onset or worsening eye symptoms to their healthcare provider.
Parasitic (Helminth) Infections: Treat patients with pre-existing helminth infections before initiating treatment with ADBRY. If patients become infected while receiving ADBRY and do not respond to antihelminth treatment, discontinue treatment with ADBRY until the infection resolves.
Risk of Infection with Live Vaccines: ADBRY may alter a patient’s immunity and increase the risk of infection following administration of live vaccines. Prior to initiating therapy with ADBRY, complete all age appropriate vaccinations according to current immunization guidelines. Avoid use of live vaccines during treatment with ADBRY. Limited data are available regarding coadministration of ADBRY with non-live vaccines.

ADVERSE REACTIONS

The most common adverse reactions (incidence ≥1%) are upper respiratory infections, conjunctivitis, injection site reactions, and eosinophilia.

USE IN SPECIFIC POPULATIONS

Pregnancy: There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to ADBRY during pregnancy. Healthcare providers are encouraged to register pregnant patients, or pregnant women may enroll themselves in the registry by calling 1-877-311-8972 or visiting https://mothertobaby.org/ongoing-study/adbry-tralokinumab/. There are limited data from the use of ADBRY in pregnant women to inform a drug-associated risk of adverse developmental outcomes. Human IgG antibodies are known to cross the placental barrier; therefore, ADBRY may be transmitted from the mother to the developing fetus.
Lactation: There are no data on the presence of tralokinumab-ldrm in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is present in breast milk. The effects of local gastrointestinal exposure and limited systemic exposure to ADBRY on the breastfed infant are unknown.
Pediatric Use: Safety and effectiveness of ADBRY have not been established in pediatric patients younger than 12 years of age.

^aSee full Terms, Conditions, and Eligibility Rules.

References:

1. Davis DMR, et al. J Am Acad Dermatol. 2024:90(2):e43-e56. doi:10.1016/j.jaad.2023.08.102 2. AAAAI/ACAAI JTF Atopic Dermatitis Guideline Panel, et al. Ann Allergy Asthma Immunol. 2024;132(3):274-312. doi:10.1016/j.anai.2023.11.009 3. Paller AS, et al. JAMA Dermatol. 2023;159(6):596-605. doi:10.1001/jamadermatol.2023.0627

Adbry Pediatric Safety (Ages 12-17)

Proven safety Day in and day out³

Adbry® has a demonstrated
pediatric safety profile

Adverse reactions occurring in ≥5% of the Adbry group through Week 16³

Explore
Dosing

View
Coverage

INDICATION

IMPORTANT SAFETY INFORMATION AND INDICATION

IMPORTANT SAFETY INFORMATION

CONTRAINDICATION

WARNINGS AND PRECAUTIONS

ADVERSE REACTIONS

USE IN SPECIFIC POPULATIONS

References:

You are leaving the AdbryHCP.com site to access the Digital Enrollment Form

You are leaving the AdbryHCP.com site to access the HCP eRx Program Certification Form

This website is for consumers only.

You are about to leave AdbryHCP.com.

Adbry Pediatric Safety (Ages 12-17)

Proven safety Day in and day out3

AS LITTLE AS $0

Adbry® has a demonstrated pediatric safety profile

Adverse reactions occurring in ≥5% of the Adbry group through Week 163

Explore Dosing

View Coverage

INDICATION

IMPORTANT SAFETY INFORMATION AND INDICATION

IMPORTANT SAFETY INFORMATION

CONTRAINDICATION

WARNINGS AND PRECAUTIONS

ADVERSE REACTIONS

USE IN SPECIFIC POPULATIONS

References:

Proven safety Day in and day out³

AS LITTLE AS ^$0

Adbry® has a demonstrated
pediatric safety profile

Adverse reactions occurring in ≥5% of the Adbry group through Week 16³

Explore
Dosing

View
Coverage